These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 2161038)

  • 1. Immune protection of infants against rotavirus gastroenteritis by a serotype 1 reassortant of bovine rotavirus WC3.
    Clark HF; Borian FE; Plotkin SA
    J Infect Dis; 1990 Jun; 161(6):1099-104. PubMed ID: 2161038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants.
    Treanor JJ; Clark HF; Pichichero M; Christy C; Gouvea V; Shrager D; Palazzo S; Offit P
    Pediatr Infect Dis J; 1995 Apr; 14(4):301-7. PubMed ID: 7603812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant WI79-9: different dose response patterns to virus surface proteins VP7 and VP4.
    Clark HF; Lawley D; Shrager D; Jean-Guillaume D; Offit PA; Whang SY; Eiden JJ; Bennett PS; Kaplan KM; Shaw AR
    Pediatr Infect Dis J; 2004 Mar; 23(3):206-11. PubMed ID: 15014293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season.
    Clark HF; Borian FE; Bell LM; Modesto K; Gouvea V; Plotkin SA
    J Infect Dis; 1988 Sep; 158(3):570-87. PubMed ID: 2842405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants.
    Bernstein DI; Smith VE; Sander DS; Pax KA; Schiff GM; Ward RL
    J Infect Dis; 1990 Nov; 162(5):1055-62. PubMed ID: 2172394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
    Vesikari T; Clark HF; Offit PA; Dallas MJ; DiStefano DJ; Goveia MG; Ward RL; Schödel F; Karvonen A; Drummond JE; DiNubile MJ; Heaton PM
    Vaccine; 2006 May; 24(22):4821-9. PubMed ID: 16621194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group.
    Bernstein DI; Glass RI; Rodgers G; Davidson BL; Sack DA
    JAMA; 1995 Apr; 273(15):1191-6. PubMed ID: 7707626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
    Vesikari T; Matson DO; Dennehy P; Van Damme P; Santosham M; Rodriguez Z; Dallas MJ; Heyse JF; Goveia MG; Black SB; Shinefield HR; Christie CD; Ylitalo S; Itzler RF; Coia ML; Onorato MT; Adeyi BA; Marshall GS; Gothefors L; Campens D; Karvonen A; Watt JP; O'Brien KL; DiNubile MJ; Clark HF; Boslego JW; Offit PA; Heaton PM;
    N Engl J Med; 2006 Jan; 354(1):23-33. PubMed ID: 16394299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants.
    Clark HF; Offit PA; Ellis RW; Eiden JJ; Krah D; Shaw AR; Pichichero M; Treanor JJ; Borian FE; Bell LM; Plotkin SA
    J Infect Dis; 1996 Sep; 174 Suppl 1():S73-80. PubMed ID: 8752294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.
    Block SL; Vesikari T; Goveia MG; Rivers SB; Adeyi BA; Dallas MJ; Bauder J; Boslego JW; Heaton PM;
    Pediatrics; 2007 Jan; 119(1):11-8. PubMed ID: 17200266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.
    Clark HF; Bernstein DI; Dennehy PH; Offit P; Pichichero M; Treanor J; Ward RL; Krah DL; Shaw A; Dallas MJ; Laura D; Eiden JJ; Ivanoff N; Kaplan KM; Heaton P
    J Pediatr; 2004 Feb; 144(2):184-90. PubMed ID: 14760258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.
    Goveia MG; Rodriguez ZM; Dallas MJ; Itzler RF; Boslego JW; Heaton PM; DiNubile MJ;
    Pediatr Infect Dis J; 2007 Dec; 26(12):1099-104. PubMed ID: 18043445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity.
    Vesikari T; Ruuska T; Green KY; Flores J; Kapikian AZ
    Pediatr Infect Dis J; 1992 Jul; 11(7):535-42. PubMed ID: 1326741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotype 1 reassortant of bovine rotavirus WC3, strain WI79-9, induces a polytypic antibody response in infants.
    Clark HF; Borian FE; Modesto K; Plotkin SA
    Vaccine; 1990 Aug; 8(4):327-32. PubMed ID: 2168607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divergence of VP7 genes of G1 rotaviruses isolated from infants vaccinated with reassortant rhesus rotaviruses.
    Jin Q; Ward RL; Knowlton DR; Gabbay YB; Linhares AC; Rappaport R; Woods PA; Glass RI; Gentsch JR
    Arch Virol; 1996; 141(11):2057-76. PubMed ID: 8973523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group.
    Rennels MB; Glass RI; Dennehy PH; Bernstein DI; Pichichero ME; Zito ET; Mack ME; Davidson BL; Kapikian AZ
    Pediatrics; 1996 Jan; 97(1):7-13. PubMed ID: 8545227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for development of a rotavirus vaccine against rotavirus diarrhea in infants and young children.
    Kapikian AZ; Flores J; Hoshino Y; Midthun K; Gorziglia M; Green KY; Chanock RM; Potash L; Sears SD; Clements ML
    Rev Infect Dis; 1989; 11 Suppl 3():S539-46. PubMed ID: 2548276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
    Dennehy PH; Goveia MG; Dallas MJ; Heaton PM
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S36-42. PubMed ID: 18162245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis.
    Joensuu J; Koskenniemi E; Pang XL; Vesikari T
    Lancet; 1997 Oct; 350(9086):1205-9. PubMed ID: 9652561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Field trial of rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. The Elmwood, Panorama, and Westfall Pediatric Groups.
    Madore HP; Christy C; Pichichero M; Long C; Pincus P; Vosefsky D; Kapikian AZ; Dolin R
    J Infect Dis; 1992 Aug; 166(2):235-43. PubMed ID: 1321858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.